SAB Biotherapeutics, Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. Although the request references 2022 Q4, this filing reports annual results; it does not provide a standalone fourth-quarter financial summary. SAB is a clinical-stage biopharmaceutical company developing fully human polyclonal antibodies through its DiversitAb platform. It had no commercially approved products, and revenue was primarily government grant funding.
Financial performance and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue, principally grants | $23.9 million | $60.9 million |
| Research and development expense | $36.4 million | $57.2 million |
| General and administrative expense | $16.4 million | $17.1 million |
| Operating loss | $28.9 million | $13.4 million |
| Net loss | $18.7 million | $17.1 million |
| Net cash used in operating activities | $23.5 million | $2.0 million provided |
| Cash and cash equivalents at year-end | $15.0 million | $33.2 million |
- Revenue fell 60.7%, mainly following termination of the approximately $203.6 million DoD JPEO Rapid Response contract. The company recognized $22.2 million from that award in 2022, versus $60.2 million in 2021.
- Operating expenses totaled $52.8 million. Lower R&D spending—especially supplies, manufacturing, and clinical-trial costs—was more than offset by the steep revenue decline, widening the operating loss.
- FY2022 net loss included a $10.4 million noncash gain from changes in warrant fair value. This helped limit the reported net loss and does not represent operating cash generation. Basic and diluted loss per share was $0.43, compared with $0.63 in 2021.
- Year-end current assets were $22.1 million and current liabilities were $15.0 million. Total notes payable were $1.3 million; finance lease liabilities were $3.8 million and operating lease liabilities were $0.9 million. Total contractual obligations, including leases, were $8.6 million.
- Financing included approximately $7.7 million net proceeds from a December 2022 private placement of 7.36 million shares and warrants. The warrants may add substantial dilution if exercised.
- Management stated that existing cash may not cover operating needs for the 12 months following issuance of the financial statements and that substantial doubt exists about the company’s ability to continue as a going concern without additional financing. No profitability or product-revenue guidance was provided.
Material changes and notable items
- The DoD notified SAB in August 2022 that it was terminating the JPEO Rapid Response contract. The company reported no termination penalties; final government payments for work and wind-down totaled approximately $16.8 million, received in November 2022 and January 2023.
- Development of SAB-185 for COVID-19 was paused amid market and commercialization uncertainty. Its Phase 3 ACTIV-2 study ended after NIH cited operational futility and the cost-prohibitive prospect of demonstrating efficacy as hospitalizations declined.
- SAB-176 met the primary endpoint in a 60-person Phase 2a influenza challenge study, reducing viral load versus placebo (one-sided p=0.026); the company reported no SAB-176-related serious adverse events in that study. Further efficacy in naturally infected, high-risk patients remained unproven.
- The 2021 financial statements and 2022 interim cash-flow statements were restated for errors in accounting for insurance-premium financing. The 2021 balance sheet was adjusted to increase both prepaid expenses and notes payable by $1.8 million; net loss and equity were unchanged. Management also disclosed that its 2021 and 2022 interim statements should no longer be relied upon as originally issued.
- Management identified a material weakness in internal control over financial reporting—insufficient accounting expertise for review of technical accounting matters and significant or unusual transactions—and concluded disclosure controls were ineffective at year-end. Remediation was underway, including added technical accounting resources and a contract-management system.
- After year-end, SAB agreed to a Ladenburg settlement involving a $0.5 million cash payment, a warrant for 300,000 shares, and further payments of $1.5 million by June 30, 2023 and $1.1 million by December 31, 2023, payable in cash or shares at the company’s option.
Outlook, risks, and contingencies
- Management expects continued losses and additional capital needs following the DoD contract termination. It plans to pursue equity or debt financing, partnerships, and other funding arrangements; funding may not be available on acceptable terms or at all.
- Near-term development plans included targeting an SAB-195 IND filing in the first quarter of 2024 and anticipating an SAB-142 IND filing on or before the first quarter of 2024. The company also expected to complete the transgenic-cattle NADA process in the fourth quarter of 2024. These are forward-looking targets, not assured outcomes.
- Key risks include clinical and regulatory failure or delay; the additional animal-drug approval needed for its Tc Bovine platform; manufacturing scale-up and supply constraints; reliance on third parties; dependence on government funding; competition; intellectual-property risks; and uncertain reimbursement and market acceptance.
- Nasdaq notified the company in January 2023 that its share price had been below the $1.00 minimum bid requirement for 30 consecutive business days, with an initial compliance deadline of July 24, 2023.
- The filing reports no material pending litigation as of its filing disclosures, but notes potential future obligations related to DoD contract wind-down negotiations and vendors. The Ladenburg settlement creates specified post-year-end payment and dilution exposure.
Most important facts for investors to verify
- Current cash runway, financing raised since the financial statements were issued, and whether management’s going-concern assessment has changed.
- Actual funding and milestone status for SAB-176, SAB-195, SAB-142, and the Tc Bovine NADA process; distinguish stated targets from completed milestones.
- Final resolution of DoD termination matters, including any vendor-related or other contingent reimbursement obligations.
- Completion and effectiveness of internal-control remediation, and any further restatements or reporting-control issues.
- Cash versus stock settlement of the Ladenburg amounts, and potential dilution from outstanding and newly issued warrants and equity awards.